BioSig Technologies Inc. Common Stock
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
BSGM Overview
Sector |
Health Care |
Industry |
Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Previous Close |
$1.1900 |
Previous Close Volume |
2490000 |
Latest News
- BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement 13 Nov 2024 15:19:39
- BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel 22 Oct 2024 15:19:49
- BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation 31 Jul 2024 09:49:58
-
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024
25 Jul 2024 14:04:52
https://ir.biosig.com/press-releases/detail/364/biosig-technologies-improves-balance-sheet-announces
- BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer 10 Jun 2024 09:50:07
- BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 30 May 2024 16:20:01
- BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 30 May 2024 08:04:59
- BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders 21 May 2024 11:19:59
- BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent 03 May 2024 12:35:02
-
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
30 Apr 2024 14:05:04
https://ir.biosig.com/press-releases/detail/358/biosig-technologies-inc-appoints-mr-anthony-amato-to
-
BioSig Announces Reduction of its Workforce
20 Feb 2024 10:05:15
https://ir.biosig.com/press-releases/detail/356/biosig-announces-reduction-of-its-workforce
-
BioSig Announces Reverse Stock Split
31 Jan 2024 11:20:11
https://ir.biosig.com/press-releases/detail/354/biosig-announces-reverse-stock-split
- BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy 30 Jan 2024 08:35:05
- BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 13 Nov 2023 17:15:26
- BioSig AI Sciences Receives $2.2 Million in Seed Funding to Advance Development of Artificial Intelligence Applications 25 Jul 2023 08:30:10